{"id":18043,"date":"2021-10-01T14:10:37","date_gmt":"2021-10-01T12:10:37","guid":{"rendered":"https:\/\/www.izb-online.de\/mediathek\/innovative-medikamentenentwickler-praesentieren-vor-ueber-20-investoren-im-muenchner-gruenderzentrum\/"},"modified":"2021-10-01T14:42:16","modified_gmt":"2021-10-01T12:42:16","slug":"innovative-medikamentenentwickler-praesentieren-vor-ueber-20-investoren-im-muenchner-gruenderzentrum","status":"publish","type":"gco_media","link":"https:\/\/www.izb-online.de\/en\/mediathek\/press-release\/innovative-drug-developers-presented-to-over-20-investors-at-the-munich-start-up-center\/","title":{"rendered":"Innovative drug developers presented to over 20 investors at the Munich Start-Up Center"},"content":{"rendered":"

[vc_row el_class=”gco-magazine-container”][vc_column el_class=”bildspalte”][vc_row_inner][vc_column_inner offset=”vc_col-lg-12 vc_col-md-12″][vc_column_text el_class=”gco-magazine–title”]<\/p>\n

Innovative drug developers presented to over 20 investors at the Munich Start-Up Center<\/h1>\n

[\/vc_column_text][vc_column_text el_class=”gco-magazine–post-date”]1.10.2021[\/vc_column_text][vc_column_text el_class=”gco-magazine-lead”]The 6th Munich Life Science Pitch Day was organized in cooperation with High-Tech Gr\u00fcnderfonds, Bayer AG, Boehringer Ingelheim and the IZB[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”gco-magazine-container–copy” css=”.vc_custom_1618289642146{margin-top: 22px !important;}”][vc_column_inner width=”2\/3″ offset=”vc_col-lg-6 vc_col-md-6″][vc_column_text]<\/p>\n


\nDownload Press Release<\/span><\/a><\/div>\n

[\/vc_column_text][vc_column_text css=”.vc_custom_1583761043671{background-color: #1e73be !important;}” el_class=”redaktionell”][\/vc_column_text][\/vc_column_inner][vc_column_inner width=”1\/3″ offset=”vc_col-lg-6 vc_col-md-6″][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”gco-magazine-container–copy”][vc_column_inner][vc_column_text]Martinsried, September 1. October, 2021 \u2013 Once again the Munich Life Science Pitch Day on the September 30, 2001 in Munich was a total success for both the project teams and the more than 20 investors. This event takes place every year in cooperation with High-Tech-Gr\u00fcnderfonds (HTGF), Bayer AG, Boehringer Ingelheim and the Innovation and Start-Up Center for Biotechnology (IZB) in Martinsried near Munich. 35 project teams from the life science sector had applied. Ten start-ups had the opportunity to present their innovative drug development projects to renowned venture capital companies. Dr. Martin Pfister, principal of HTGF moderated the event and introduced the HTGF. Dr. Peter Hanns Zobel, Managing Director of the IZB, gave a glimps into the dynamic Start-Up Center IZB. Dr. John-Edward Butler-Ransohoff, Vice President Open Innovation – Public Private Partnership, Bayer AG explained what kinds of cooperation models exist at Bayer AG. The participants followed the fireside chat with Dr. Martin Pfister and Dr. Ingmar Hoerr, founder of CureVac AG with great interest.<\/p>\n

The following investors attended this event: Abbvie, Apollo Health Ventures, Bayer, Bayern Capital, BioMed Partners, bmp Ventures, Boehringer Ingelheim, Coparion, Forbion Capital Partners, Hadean Ventures, HTGF, KURMA Partners, Long VC, LSP, mbc, Maximon, Medi Ventures, Occident Group, Seventure, TVM Capital, Vantage Value, Vesalius Biocapital and Wellington Partners.<\/p>\n

\u201cWe are pleased to be able to give start-ups the opportunity every year to present before top-class venture capital companies in order to establish contacts with investors at an early stage. I would very much like to thank our long-term partners, who leave with an extremely positive impression of the Munich start-up scene,” explains Dr. Peter Hanns Zobel, Managing Director of the IZB.<\/p>\n

\u201cWith the Munich Life Science Pitch Day we have established an outstanding event together with the IZB, Bayer AG and Boehringer Ingelheim, which has taken place for the sixth time in Munich. This is where partnerships emerge from which the life science start-ups and all participating investors benefit. At the same time, all participants gain valuable insights into the innovative strength of young start-ups. This is real added value for everyone involved. We are already looking forward to the next Pitch Day,\u201d according to Dr. Caroline Fichtner, Principal of HTF.<\/p>\n

\u201cThe Life Science Pitch Day offers the best possible framework for targeted networking with established investors. The ten participating life science start-ups impressed us with their innovative ideas. It was also a pleasure for me to round off the event in an interesting conversation with our guest Ingmar Hoerr, founder of CureVac,\u201d says Dr. Martin Pfister, Principal of HTGF.<\/p>\n

“A central aspect of a pitch event is networking. The founders have the chance to make important contacts with potential investors and partners. And it is precisely this exchange that is made possible at the Life Science Pitch Day in Munich. I was very impressed by the quality of the young start-ups’ research. It was great to follow the lively exchange and get to know the start-ups,” explains Dr. John-Edward Butler-Ransohoff, Vice President Open Innovation – Public Private Partnership, Bayer AG.<\/p>\n

“At the Life Science Pitch Day, interesting partnerships and synergies can emerge between investor:ing and the innovative founder:ing scene. Events like these make a valuable contribution to promoting innovation and opening up new horizons for completely new therapeutic approaches for patients. The quality of the founding teams and the forward-looking solutions of the pitching start-ups are a real enrichment for the life science sector,” says Alexander Ehlgen, Boehringer Ingelheim Venture Fund.[\/vc_column_text][vc_column_text css=”.vc_custom_1633092135267{margin-top: 15px !important;}”]The investors were enthusiastic about the innovative drug developers. The following project teams presented at the “6th<\/sup> Munich Life Science Pitch Day”:<\/strong><\/p>\n

    \n
  1. Dimericon, Ulrich Kessler: Dimericon, Ulrich Kessler: Fighting cancer \u2013 A novel therapeutic modality conquering the plasticity conundrum in IDP-targeted oncology drug discovery<\/li>\n
  2. Fundamental Pharma, Thomas Schulze: Next generation brain drugs acting as molecular spacers to halt neurodegeneration<\/li>\n
  3. FUSIX Biotech, Jennifer Altomonte: A TUM spin-off developing a “best-in-class” oncolytic virus platform to treat solid tumors<\/li>\n
  4. Galimedix, Alexander Gebauer: Breakthrough therapy in Alzheimer\u00b4s disease:
    \nSmall molecule GAL-201 for cognitive improvement and neuroprotection<\/li>\n
  5. Intellexon, Christoph Winterhalter: Intellexon uncovered new embryo-fetal HLAs as unique tumor targets<\/li>\n
  6. Invasight, Karthiga Santhana Kumar: Developing potent and safe first-in-class, protein-protein interaction inhibitors against invasive cancers<\/li>\n
  7. OPSYON, Nadja Fenn: OPSYON’s vision and mission is to combine direct cancer cell targeting with the benefits of immune checkpoint inhibition in one molecule to maximize anti-cancer efficacy while minimizing unwanted side effects.<\/li>\n
  8. RecTec, Anne-Kristin Heninger: It is our vision to establish designer recombinases as the leading technology for safe and precise genome surgery to cure genetic diseases.<\/li>\n
  9. Riana Therapeutics, Anna Orlova: We develop novel first-in-class treatment options against cancer<\/li>\n
  10. Sirana Pharma, Hermann-Josef Kaiser: Restoring musculoskeletal health<\/li>\n<\/ol>\n

    [\/vc_column_text][vc_column_text css=”.vc_custom_1583761043671{background-color: #1e73be !important;}” el_class=”redaktionell”][\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner][vc_column_inner][vc_single_image image=”18042″ img_size=”full”][vc_column_text el_class=”gco-magazine-copyright”]\u00a9 IZB[\/vc_column_text][vc_column_text el_class=”gco-magazine-picture-discription”]Investors of the 6th<\/sup> Munich Life Science Pitch Day 2021 (v.l.n.r.): Rajput Ashish, LongeVC and Maximon; C\u00e9dric Barra, Occident Group; Philipp Kopp, mbc; Catello Somma, TVM; Daniel Parara, Kurma Partners; Ivan Morace, Medi Ventures; Dimitriy Hristodorov, Forbion Captial Partners; Mario Richter, Abbvie; Kilian S\u00f6rgel, Vantage Value; Jakob Lilienweis, HTGF; Dr. John E.Butler-Ransohoff, Bayer AG; Sascha Berger, TVM; Laura Pedroza, HTGF; Christian Schneider, Vesalius Biocapital; Markus Dietrich, Hadean Ventures, Dr. Marianne Mertens, Apollo Health Ventures; Karl N\u00e4gler, Wellington Partners; Joachim Vogt, Abbvie; Thomas M\u00f6ller, BioMed Partners; Andreas Huber, Bayern Kapital; Dr. Fei Tian, Vesalius Biocapital; Philipp Br\u00e4uer LSP; Johannes Fischer, Wellington Partners; Aagam Shah, Occident Group (f.l.t.r.):[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”two-columns”][vc_column_inner el_class=”bild-zwei-spalten-links”][vc_single_image image=”18038″ img_size=”full”][vc_column_text el_class=”gco-magazine-copyright”]\u00a9 IZB[\/vc_column_text][vc_column_text el_class=”gco-magazine-picture-discription”]Project teams of the 6th<\/sup> Munich Life Science Pitch Day 2021 (v.l.n.r.): Anna Orlova, RIANA Therapeutics, Hermann Kaiser, Sirana Pharma, Anne Kristin Heinger RECTECH (First row f.l.t.r.), Nadja Fenn, OPSYON; Ulrich Kessler, DIMERICON THERAPEUTICS; Alexander Gebauer, Galimedix; Christoph Winterhalter, INTELLEXON; Thomas Schulze, Fundamental Pharma; Karthiga Santhana Kumar, INVASIGHT; Jennifer Altomonte, FUSIX Biotech (Second row f.l.t.r.)[\/vc_column_text][vc_single_image image=”18040″ img_size=”full”][vc_column_text el_class=”gco-magazine-copyright”]\u00a9 IZB[\/vc_column_text][vc_column_text el_class=”gco-magazine-picture-discription”]Partner of the 6th<\/sup> Munich Life Science Pitch Day 2021 at the IZB: Dr. John E.Butler-Ransohoff, Vice President Open Innovation \u2013 Public Private Partnership, Bayer AG; Dr. Martin Pfister, Principal HTGF; Dr. Peter Hanns Zobel, Managing Director IZB (f.l.t.r)[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner css=”.vc_custom_1633091232535{margin-top: 32px !important;}”][vc_column_inner][vc_column_text]Pressefotos zum Download unter:
    \n<\/strong>    https:\/\/www.izb-online.de\/mediathek\/6th-munich-life-science-pitch-day\/<\/a>[\/vc_column_text][vc_column_text css=”.vc_custom_1583761043671{background-color: #1e73be !important;}” el_class=”redaktionell”][\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”gco-magazine-container–copy” css=”.vc_custom_1633091148654{margin-top: 32px !important;}”][vc_column_inner][vc_column_text]About Innovation and Start-up Center for Biotechnology (IZB) in Martinsried near Munich
    \n<\/strong>The F\u00f6rdergesellschaft IZB mbH, founded in 1995, is the operating company of the Innovation and Start-up Centers for Biotechnology in Planegg-Martinsried and Freising-Weihenstephan, and has developed into a leading biotechnology center. More than 50 biotech companies with over 700 employees are currently located on 26,000 m2 <\/sup>of land. Here, work focuses on the development of drugs against the most serious diseases, such as cancer, Alzheimer’s and various autoimmune diseases. A key criterion for the success of the IZBs is their close proximity to top-level research at both the Martinsried\/Grosshadern campus and the Weihenstephan campus. The new infrastructure measures such as the Faculty Club G2B (Gateway to Biotech), the IZB Residence CAMPUS AT HOME, the Elhardt Chemistry College, the two kindergartens Bio Kids and Bio Kids2<\/sup>, as well as the two restaurants SEVEN AND MORE and Caf\u00e9 Freshmaker are also location factors that are highly appreciated by the company founders. Successful companies that have emerged from the IZB include Medigene AG, MorphoSys AG, Micromet GmbH (today Amgen AG), Octopharma GmbH, Corimmun (today Janssen-Cilag), Rigontec GmbH (today MSD), ibidi GmbH, Coriolis GmbH and Immunic Therapeutics. More information at     www.izb-online.de<\/a><\/p>\n

    Press contact and image requests:
    \n<\/strong>Susanne Simon, Head of Public Relations
    \nF\u00f6rdergesellschaft IZB mbH
    \nAm Klopferspitz 19
    \nD-82152 Planegg Martinsried
    \nPhone: +49 (0)89\/55 279 48-17,
    \n    simon@izb-online.de<\/a>
    \n    www.izb-online.de<\/a><\/p>\n

    About High-Tech Gr\u00fcnderfonds
    \n<\/strong>High-Tech Gr\u00fcnderfonds (HTGF) is a seed investor that finances high-potential, tech-driven start-ups. With around EUR 900 million in total investment volume across three funds and an international network of partners, HTGF has already helped forge more than 650 start-ups since 2005. Driven by their expertise, entrepreneurial spirit and passion, its team of experienced investment managers and startup experts help guide the development of young companies. HTGF\u2019s focus is on high-tech start-ups in the fields of digital tech, industrial technology, life sciences, chemistry and related business areas. To date, external investors have injected more than EUR 3 billion into the HTGF portfolio via more than 1,800 follow-on financing rounds. HTGF has also successfully sold interests in more than 140 companies.<\/p>\n

    Investors in this public-private partnership include the Federal Ministry For Economic Affairs and Energy, KfW Capital, and Fraunhofer-Gesellschaft e.V., as well as the companies ALTANA, BASF, BAYER, B.Braun, Boehringer Ingelheim, Robert Bosch, B\u00dcFA, CEWE, Deutsche Bank, Deutsche Post DHL, Dr\u00e4ger, 1+1 AG, EVONIK, EWE AG, FOND OF, Haniel, Hettich, Knauf, K\u00f6rber, LANXESS, media + more venture Beteiligungs GmbH & Co. KG, PHOENIX CONTACT, QIAGEN, RWE Generation SE, SAP, Schufa, Schwarz Gruppe, STIHL, Th\u00fcga, Vector Informatik, WACKER and Wilh. Werhahn KG. www.htgf.de\/en<\/a><\/p>\n

    Media Contact<\/strong>
    \nHigh-Tech Gr\u00fcnderfonds Management GmbH
    \nStefanie Gr\u00fcter, Head of Marketing & Communications
    \nT.: +49 228 \u2013 82300 \u2013 188    s.grueter@htgf.de<\/a>[\/vc_column_text][vc_column_text css=”.vc_custom_1583761043671{background-color: #1e73be !important;}” el_class=”redaktionell”][\/vc_column_text][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"featured_media":17494,"template":"","meta":{"_links_to":"","_links_to_target":""},"media-categories":[7432,7431],"class_list":["post-18043","gco_media","type-gco_media","status-publish","has-post-thumbnail","hentry","media-categories-press-release","media-categories-press-release-izb-martinsried"],"yoast_head":"\nInnovative drug developers presented to over 20 investors at the Munich Start-Up Center - Innovations- und Gr\u00fcnderzentrum Biotechnologie IZB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.izb-online.de\/en\/mediathek\/press-release\/innovative-drug-developers-presented-to-over-20-investors-at-the-munich-start-up-center\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Innovative drug developers presented to over 20 investors at the Munich Start-Up Center\" \/>\n<meta property=\"og:description\" content=\"Innovative drug developers presented to over 20 investors at the Munich Start-Up Center 1.10.2021The 6th Munich Life Science Pitch Day was organized in\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.izb-online.de\/en\/mediathek\/press-release\/innovative-drug-developers-presented-to-over-20-investors-at-the-munich-start-up-center\/\" \/>\n<meta property=\"og:site_name\" content=\"Innovations- und Gr\u00fcnderzentrum Biotechnologie IZB\" \/>\n<meta property=\"article:modified_time\" content=\"2021-10-01T12:42:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.izb-online.de\/wp-content\/uploads\/2021\/07\/izb-logo-presse-e1625133835965.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"725\" \/>\n\t<meta property=\"og:image:height\" content=\"272\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/mediathek\\\/press-release\\\/innovative-drug-developers-presented-to-over-20-investors-at-the-munich-start-up-center\\\/\",\"url\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/mediathek\\\/press-release\\\/innovative-drug-developers-presented-to-over-20-investors-at-the-munich-start-up-center\\\/\",\"name\":\"Innovative drug developers presented to over 20 investors at the Munich Start-Up Center - Innovations- und Gr\u00fcnderzentrum Biotechnologie IZB\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/mediathek\\\/press-release\\\/innovative-drug-developers-presented-to-over-20-investors-at-the-munich-start-up-center\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/mediathek\\\/press-release\\\/innovative-drug-developers-presented-to-over-20-investors-at-the-munich-start-up-center\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.izb-online.de\\\/wp-content\\\/uploads\\\/2021\\\/07\\\/izb-logo-presse-e1625133835965.jpg\",\"datePublished\":\"2021-10-01T12:10:37+00:00\",\"dateModified\":\"2021-10-01T12:42:16+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/mediathek\\\/press-release\\\/innovative-drug-developers-presented-to-over-20-investors-at-the-munich-start-up-center\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.izb-online.de\\\/en\\\/mediathek\\\/press-release\\\/innovative-drug-developers-presented-to-over-20-investors-at-the-munich-start-up-center\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/mediathek\\\/press-release\\\/innovative-drug-developers-presented-to-over-20-investors-at-the-munich-start-up-center\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.izb-online.de\\\/wp-content\\\/uploads\\\/2021\\\/07\\\/izb-logo-presse-e1625133835965.jpg\",\"contentUrl\":\"https:\\\/\\\/www.izb-online.de\\\/wp-content\\\/uploads\\\/2021\\\/07\\\/izb-logo-presse-e1625133835965.jpg\",\"width\":725,\"height\":272},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/mediathek\\\/press-release\\\/innovative-drug-developers-presented-to-over-20-investors-at-the-munich-start-up-center\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"PRESS RELEASE\",\"item\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/media-library\\\/press-release\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Press release standard\",\"item\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/media-library\\\/press-release\\\/press-release-izb-martinsried\\\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Innovative drug developers presented to over 20 investors at the Munich Start-Up Center\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/\",\"name\":\"Innovations- und Gr\u00fcnderzentrum Biotechnologie IZB\",\"description\":\"Innovations- und Gr\u00fcnderzentrum Biotechnologie\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/#organization\",\"name\":\"F\u00f6rdergesellschaft IZB mbH\",\"url\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.izb-online.de\\\/wp-content\\\/uploads\\\/2020\\\/06\\\/izb-logo.svg\",\"contentUrl\":\"https:\\\/\\\/www.izb-online.de\\\/wp-content\\\/uploads\\\/2020\\\/06\\\/izb-logo.svg\",\"width\":1,\"height\":1,\"caption\":\"F\u00f6rdergesellschaft IZB mbH\"},\"image\":{\"@id\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Innovative drug developers presented to over 20 investors at the Munich Start-Up Center - Innovations- und Gr\u00fcnderzentrum Biotechnologie IZB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.izb-online.de\/en\/mediathek\/press-release\/innovative-drug-developers-presented-to-over-20-investors-at-the-munich-start-up-center\/","og_locale":"en_US","og_type":"article","og_title":"Innovative drug developers presented to over 20 investors at the Munich Start-Up Center","og_description":"Innovative drug developers presented to over 20 investors at the Munich Start-Up Center 1.10.2021The 6th Munich Life Science Pitch Day was organized in","og_url":"https:\/\/www.izb-online.de\/en\/mediathek\/press-release\/innovative-drug-developers-presented-to-over-20-investors-at-the-munich-start-up-center\/","og_site_name":"Innovations- und Gr\u00fcnderzentrum Biotechnologie IZB","article_modified_time":"2021-10-01T12:42:16+00:00","og_image":[{"width":725,"height":272,"url":"https:\/\/www.izb-online.de\/wp-content\/uploads\/2021\/07\/izb-logo-presse-e1625133835965.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.izb-online.de\/en\/mediathek\/press-release\/innovative-drug-developers-presented-to-over-20-investors-at-the-munich-start-up-center\/","url":"https:\/\/www.izb-online.de\/en\/mediathek\/press-release\/innovative-drug-developers-presented-to-over-20-investors-at-the-munich-start-up-center\/","name":"Innovative drug developers presented to over 20 investors at the Munich Start-Up Center - Innovations- und Gr\u00fcnderzentrum Biotechnologie IZB","isPartOf":{"@id":"https:\/\/www.izb-online.de\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.izb-online.de\/en\/mediathek\/press-release\/innovative-drug-developers-presented-to-over-20-investors-at-the-munich-start-up-center\/#primaryimage"},"image":{"@id":"https:\/\/www.izb-online.de\/en\/mediathek\/press-release\/innovative-drug-developers-presented-to-over-20-investors-at-the-munich-start-up-center\/#primaryimage"},"thumbnailUrl":"https:\/\/www.izb-online.de\/wp-content\/uploads\/2021\/07\/izb-logo-presse-e1625133835965.jpg","datePublished":"2021-10-01T12:10:37+00:00","dateModified":"2021-10-01T12:42:16+00:00","breadcrumb":{"@id":"https:\/\/www.izb-online.de\/en\/mediathek\/press-release\/innovative-drug-developers-presented-to-over-20-investors-at-the-munich-start-up-center\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.izb-online.de\/en\/mediathek\/press-release\/innovative-drug-developers-presented-to-over-20-investors-at-the-munich-start-up-center\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.izb-online.de\/en\/mediathek\/press-release\/innovative-drug-developers-presented-to-over-20-investors-at-the-munich-start-up-center\/#primaryimage","url":"https:\/\/www.izb-online.de\/wp-content\/uploads\/2021\/07\/izb-logo-presse-e1625133835965.jpg","contentUrl":"https:\/\/www.izb-online.de\/wp-content\/uploads\/2021\/07\/izb-logo-presse-e1625133835965.jpg","width":725,"height":272},{"@type":"BreadcrumbList","@id":"https:\/\/www.izb-online.de\/en\/mediathek\/press-release\/innovative-drug-developers-presented-to-over-20-investors-at-the-munich-start-up-center\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.izb-online.de\/en\/"},{"@type":"ListItem","position":2,"name":"PRESS RELEASE","item":"https:\/\/www.izb-online.de\/en\/media-library\/press-release\/"},{"@type":"ListItem","position":3,"name":"Press release standard","item":"https:\/\/www.izb-online.de\/en\/media-library\/press-release\/press-release-izb-martinsried\/"},{"@type":"ListItem","position":4,"name":"Innovative drug developers presented to over 20 investors at the Munich Start-Up Center"}]},{"@type":"WebSite","@id":"https:\/\/www.izb-online.de\/en\/#website","url":"https:\/\/www.izb-online.de\/en\/","name":"Innovations- und Gr\u00fcnderzentrum Biotechnologie IZB","description":"Innovations- und Gr\u00fcnderzentrum Biotechnologie","publisher":{"@id":"https:\/\/www.izb-online.de\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.izb-online.de\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.izb-online.de\/en\/#organization","name":"F\u00f6rdergesellschaft IZB mbH","url":"https:\/\/www.izb-online.de\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.izb-online.de\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.izb-online.de\/wp-content\/uploads\/2020\/06\/izb-logo.svg","contentUrl":"https:\/\/www.izb-online.de\/wp-content\/uploads\/2020\/06\/izb-logo.svg","width":1,"height":1,"caption":"F\u00f6rdergesellschaft IZB mbH"},"image":{"@id":"https:\/\/www.izb-online.de\/en\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.izb-online.de\/en\/wp-json\/wp\/v2\/gco_media\/18043","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.izb-online.de\/en\/wp-json\/wp\/v2\/gco_media"}],"about":[{"href":"https:\/\/www.izb-online.de\/en\/wp-json\/wp\/v2\/types\/gco_media"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.izb-online.de\/en\/wp-json\/wp\/v2\/media\/17494"}],"wp:attachment":[{"href":"https:\/\/www.izb-online.de\/en\/wp-json\/wp\/v2\/media?parent=18043"}],"wp:term":[{"taxonomy":"media-categories","embeddable":true,"href":"https:\/\/www.izb-online.de\/en\/wp-json\/wp\/v2\/media-categories?post=18043"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}